MA27988A1 - Anticorps modifiés contre le IGF-1R humain - Google Patents

Anticorps modifiés contre le IGF-1R humain

Info

Publication number
MA27988A1
MA27988A1 MA28790A MA28790A MA27988A1 MA 27988 A1 MA27988 A1 MA 27988A1 MA 28790 A MA28790 A MA 28790A MA 28790 A MA28790 A MA 28790A MA 27988 A1 MA27988 A1 MA 27988A1
Authority
MA
Morocco
Prior art keywords
human igf
against human
antibody modified
igf
modified against
Prior art date
Application number
MA28790A
Other languages
English (en)
Inventor
Bruce David Cohen
Vahe Bedian
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27988A1 publication Critical patent/MA27988A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Anticorps modifiés contre le IGF-1R humain La présente invention concerne des anticorps humains, par exemple ceux dirigés contre le récepteur de IGF-1 humain (IGF-1R) qui sont destinés au traitement du cancer, qui possèdent un ou plusieurs résidus mutés choisis remplacés par des résidus de lignée germinale. Un résidu remplacé peut être une mutation somatique dans une région de squelette structural.
MA28790A 2003-08-13 2006-02-13 Anticorps modifiés contre le IGF-1R humain MA27988A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49520003P 2003-08-13 2003-08-13

Publications (1)

Publication Number Publication Date
MA27988A1 true MA27988A1 (fr) 2006-07-03

Family

ID=34193291

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28790A MA27988A1 (fr) 2003-08-13 2006-02-13 Anticorps modifiés contre le IGF-1R humain

Country Status (37)

Country Link
US (2) US7371378B2 (fr)
EP (1) EP1656391B1 (fr)
JP (1) JP4638870B2 (fr)
KR (1) KR100825156B1 (fr)
CN (1) CN1835975B (fr)
AP (1) AP2006003510A0 (fr)
AR (1) AR045247A1 (fr)
AT (1) ATE484525T1 (fr)
AU (1) AU2004265152A1 (fr)
BR (1) BRPI0413466A (fr)
CA (1) CA2535071A1 (fr)
CL (1) CL2004002035A1 (fr)
CR (1) CR8233A (fr)
DE (1) DE602004029581D1 (fr)
DK (1) DK1656391T3 (fr)
EA (1) EA200600234A1 (fr)
EC (1) ECSP066359A (fr)
ES (1) ES2351395T3 (fr)
GT (1) GT200400158A (fr)
IL (1) IL173273A (fr)
IS (1) IS8266A (fr)
MA (1) MA27988A1 (fr)
MX (1) MXPA06001634A (fr)
NL (1) NL1026829C2 (fr)
NO (1) NO20060542L (fr)
OA (1) OA13234A (fr)
PA (1) PA8608801A1 (fr)
PE (1) PE20050339A1 (fr)
PL (1) PL1656391T3 (fr)
PT (1) PT1656391E (fr)
RS (1) RS20060099A (fr)
TN (1) TNSN06050A1 (fr)
TW (1) TWI294915B (fr)
UA (1) UA85058C2 (fr)
UY (1) UY28464A1 (fr)
WO (1) WO2005016967A2 (fr)
ZA (1) ZA200601231B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0116728B1 (pt) 2001-01-05 2018-10-30 Pfizer Inc. anticorpos para receptor de fator de crescimento i semelhante à insulina
US7217796B2 (en) 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
WO2005016970A2 (fr) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Anticorps entierement humains diriges contre le recepteur du facteur de croissance 1 de type insuline
MXPA06001634A (es) * 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.
JP2007510434A (ja) 2003-11-12 2007-04-26 シェーリング　コーポレイション 多重遺伝子発現のためのプラスミドシステム
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
KR20070036130A (ko) 2004-07-16 2007-04-02 화이자 프로덕츠 인코포레이티드 항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
EP2283831A3 (fr) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomarqueurs pour la présélection des patients pour la thérapie anti-IGF1R
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0500417D0 (en) * 2005-01-10 2005-02-16 Cambridge Antibody Tech Method of mutagenesis
WO2006113483A2 (fr) * 2005-04-15 2006-10-26 Schering Corporation Methodes et compositions pour le traitement ou la prevention du cancer
KR20080019249A (ko) * 2005-06-15 2008-03-03 쉐링 코포레이션 안정한 항체 제형
CA2612449A1 (fr) 2005-06-17 2006-12-28 Imclone Systems Incorporated Antagonistes de recepteur pour le traitement de cancer osseux metastatique
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
JP5198289B2 (ja) * 2006-02-03 2013-05-15 イムクローン・リミテッド・ライアビリティ・カンパニー 前立腺癌の治療用アジュバントとしてのｉｇｆ−ｉｒアンタゴニスト
WO2007110339A1 (fr) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Formulation d'anticorps monoclonal humain anti-igf-1r
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
MX2008015425A (es) * 2006-06-02 2008-12-12 Pfizer Prod Inc Ensayo de celulas tumorales circulantes.
US20090068110A1 (en) * 2006-12-22 2009-03-12 Genentech, Inc. Antibodies to insulin-like growth factor receptor
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
AU2012203443B2 (en) * 2007-03-02 2014-03-06 Amgen Inc. Methods and compositions for treating tumor diseases
US20100166747A1 (en) * 2007-03-02 2010-07-01 Beltran Pedro J Methods and compositions for treating tumor diseases
AU2008228823A1 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
EP2145021A2 (fr) 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarqueurs et procédés pour déterminer la sensibilité de modulateurs de récepteur de facteur de croissance de type 1 semblable à l'insuline
CN101903401B (zh) 2007-12-21 2013-06-05 罗切格利卡特公司 抗体的稳定性试验
CA2718918A1 (fr) * 2008-03-25 2009-11-26 Schering Corporation Procedes de traitement ou de prevention de cancer colorectal
JP2011519868A (ja) * 2008-05-05 2011-07-14 シェーリング コーポレイション 癌を処置するための化学療法剤の連続投与
US20110313134A1 (en) * 2008-11-06 2011-12-22 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
WO2010099139A2 (fr) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Thérapie anti-cancer combinée
EP2236139A1 (fr) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Thérapie combinée d'erlotinibe avec un anticorps anti-IGF-1R, qui n'inhibe pas la liaison d'insuline dans le récepteur d'insuline
WO2010146059A2 (fr) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarqueurs pour une thérapie par inhibiteur d'igf-1r
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
WO2011051231A1 (fr) 2009-10-26 2011-05-05 F. Hoffmann-La Roche Ag Procédé de fabrication d'une immunoglobuline glycosyle
EP2494070A2 (fr) 2009-10-30 2012-09-05 Bristol-Myers Squibb Company Méthodes pour traiter un cancer chez des patients présentant une résistance à l'inhibiteur d'igf-1r
CA2777527C (fr) 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Procede pour faire baisser l'immunogenicite
AU2014262201B2 (en) * 2009-12-23 2016-09-15 Novartis Ag Method for decreasing immunogenicity
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
WO2011161119A1 (fr) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Anticorps contre le récepteur du facteur de croissance insulinique i et ses utilisations
WO2012007896A1 (fr) 2010-07-12 2012-01-19 Covx Technologies Ireland, Ltd. Conjugués d'anticorps multifonctionnels
CA2825894C (fr) 2011-02-02 2021-11-30 Amgen Inc. Pronostic de cancer au moyen de biomarqueur en circulation
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
WO2013056069A1 (fr) 2011-10-13 2013-04-18 Bristol-Myers Squibb Company Procédés de sélection et de traitement du cancer chez des patients au moyen d'inhibiteurs de l'igf-1r/ir
TW201341401A (zh) 2012-01-09 2013-10-16 Covx Technologies Ireland Ltd 突變抗體及其共軛
EP2631653A1 (fr) 2012-02-24 2013-08-28 Charité - Universitätsmedizin Berlin Identification de modulateurs de liaison des propriétés d'anticorps réactifs avec un élément de la famille des récepteurs de l'insuline
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
JP2015535005A (ja) * 2012-11-06 2015-12-07 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療
KR20210094669A (ko) 2013-04-29 2021-07-29 에프. 호프만-라 로슈 아게 인간 fcrn-결합 변형된 항체 및 사용 방법
RU2687043C2 (ru) 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN103319598B (zh) * 2013-05-13 2014-10-22 杭州德同生物技术有限公司 抗胰岛素样生长因子-1受体抗体及其编码基因和应用
RU2698969C2 (ru) 2014-01-15 2019-09-02 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с улучшенной способностью связываться с белком а
US12049493B2 (en) 2017-01-06 2024-07-30 Abl Bio Inc. Anti-alpha-synuclein antibodies and uses thereof
IL272227B2 (en) * 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
US12071483B1 (en) 2017-12-14 2024-08-27 Abl Bio Inc. Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
CA2219361C (fr) 1995-04-27 2012-02-28 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
IL118626A0 (en) * 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibody
EP0923585B1 (fr) 1996-07-18 2002-05-08 Pfizer Inc. Composes a base de phosphinate inhibiteurs des metalloproteases matricielles
WO1998007697A1 (fr) 1996-08-23 1998-02-26 Pfizer Inc. Derives de l'acide arylsulfonylamino hydroxamique
KR20010071271A (ko) 1998-05-15 2001-07-28 존 비. 랜디스 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
SI2168984T1 (sl) 1999-03-25 2012-12-31 Abbott Gmbh & Co. Kg Človeška protitelesa za vezavo IL-12 in postopki izdelave
ES1042735Y (es) 1999-04-07 2000-02-16 Martinez Fernando Martinez Vehiculo tripersonal de accionamiento a pedales.
US20030165502A1 (en) 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
DE10033869C2 (de) 2000-07-12 2003-07-31 Karlsruhe Forschzent HTS-Kryomagnet und Aufmagnetisierungsverfahren
BRPI0116728B1 (pt) * 2001-01-05 2018-10-30 Pfizer Inc. anticorpos para receptor de fator de crescimento i semelhante à insulina
ES2398099T3 (es) 2001-02-19 2013-03-13 Merck Patent Gmbh Anticuerpos anti-EGFR modificados con inmunogenicidad reducida
DE60312639T2 (de) 2002-01-18 2007-11-29 Pierre Fabre Médicament Antikörper gegen igf-ir und ihre verwendungen
JP4335130B2 (ja) 2002-04-30 2009-09-30 協和発酵キリン株式会社 ヒトインスリン様成長因子に対する抗体
US7217796B2 (en) * 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
GB0212303D0 (en) 2002-05-28 2002-07-10 Isis Innovation Molecular targetting of IGF-1 receptor
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
AU2004212344B2 (en) 2003-02-13 2009-05-07 Pfizer Products Inc. Uses of anti-insulin-like growth factor I receptor antibodies
WO2004083248A1 (fr) 2003-03-14 2004-09-30 Pharmacia Corporation Anticorps specifiques du recepteur d'igf-i pour le traitement de cancers
EP1613658B1 (fr) 2003-04-02 2012-03-14 F. Hoffmann-La Roche AG Anticorps contre le recepteur du facteur de croissance 1 analogue a l'insuline et utilisations de ceux-ci
MXPA06001634A (es) * 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.

Also Published As

Publication number Publication date
US20080181891A1 (en) 2008-07-31
ECSP066359A (es) 2006-10-31
NO20060542L (no) 2006-05-03
UY28464A1 (es) 2005-03-31
DE602004029581D1 (de) 2010-11-25
EA200600234A1 (ru) 2006-08-25
AU2004265152A1 (en) 2005-02-24
IL173273A (en) 2011-10-31
JP4638870B2 (ja) 2011-02-23
CR8233A (es) 2007-01-18
UA85058C2 (ru) 2008-12-25
IS8266A (is) 2006-01-26
US7575746B2 (en) 2009-08-18
GT200400158A (es) 2005-07-22
MXPA06001634A (es) 2006-04-28
OA13234A (en) 2006-12-13
IL173273A0 (en) 2006-06-11
RS20060099A (sr) 2008-08-07
EP1656391B1 (fr) 2010-10-13
KR100825156B1 (ko) 2008-04-24
DK1656391T3 (da) 2011-01-03
US20050069539A1 (en) 2005-03-31
PE20050339A1 (es) 2005-05-17
CN1835975B (zh) 2012-11-21
PT1656391E (pt) 2010-12-06
TWI294915B (en) 2008-03-21
CL2004002035A1 (es) 2005-06-03
ZA200601231B (en) 2007-05-30
KR20060035796A (ko) 2006-04-26
ATE484525T1 (de) 2010-10-15
TW200516145A (en) 2005-05-16
BRPI0413466A (pt) 2006-10-17
ES2351395T3 (es) 2011-02-04
TNSN06050A1 (fr) 2007-10-03
PA8608801A1 (es) 2005-03-03
WO2005016967A3 (fr) 2005-04-14
AR045247A1 (es) 2005-10-19
US7371378B2 (en) 2008-05-13
WO2005016967A2 (fr) 2005-02-24
EP1656391A2 (fr) 2006-05-17
NL1026829C2 (nl) 2005-07-05
AP2006003510A0 (en) 2006-02-28
CA2535071A1 (fr) 2005-02-24
CN1835975A (zh) 2006-09-20
NL1026829A1 (nl) 2005-02-15
JP2007527705A (ja) 2007-10-04
PL1656391T3 (pl) 2011-03-31

Similar Documents

Publication Publication Date Title
MA27988A1 (fr) Anticorps modifiés contre le IGF-1R humain
FR22C1052I1 (fr) Anticorps anti-cd19 humanises et leur utilisation dans le traitement des tumeurs, de la transplantation et des maladies auto-immunes
MA29374B1 (fr) Anticorps anti-ccr5 et leurs utilisations
EP2275134A3 (fr) Utilisation d'anticorps optimisés en ADCC pour traiter les patients faibles répondeurs
MA33387B1 (fr) Polypeptides et procede de traitement
MA39313A1 (fr) Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
ATE477276T1 (de) Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
MA43328A1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
MA35174B1 (fr) Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
MA43435B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003)
PE20061040A1 (es) Anticuerpos antiamiloides humanizados
MX2018005512A (es) Agentes de union de esclerostina.
MA33276B1 (fr) Anticorps spécifiques à la cadhérine-17
PE20061115A1 (es) Anticuerpos anti-il-12, epitopos, composiciones, metodos y usos
MA35345B1 (fr) Proteines de liaisons a un antigene ayant une liaison accrue a fcrn
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
WO2007042573A3 (fr) Compositions et procedes pour traiter des troubles de proliferation
EP1893196A4 (fr) Composes diarylhydantoines
MY174493A (en) Binding agents
CY1114019T1 (el) Μεταλλακτες του αντισωματος anti-cd40
UA92505C2 (ru) Композиции на основе антитела против cd3
EP1470146A4 (fr) Anticorps contre l'antigene muc18
WO2019032945A9 (fr) Agent liant cd40 et utilisations associées
EP1828404A4 (fr) Dispositifs et procédés permettant de déterminer l'activité d'une protéase